Investigational New Drug Contract Development and Manufacturing Organization (CDMO) Market Report 2026

The investigational new drug contract development and manufacturing organization (cdmo) market size has grown strongly in recent years. It will grow from $5.91 billion in 2025 to $6.33 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to limited availability of cdmos for investigational drugs, growing demand for small molecule synthesis, reliance on conventional manufacturing services, increasing clinical trial volumes, early adoption of regulatory support services.

The investigational new drug contract development and manufacturing organization (cdmo) market size is expected to see strong growth in the next few years. It will grow to $8.17 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expansion of gene and cell therapy manufacturing capabilities, rising demand for monoclonal antibodies and recombinant proteins, investment in advanced formulation technologies, adoption of scalable manufacturing platforms, growth in global biotechnology research collaborations. Major trends in the forecast period include rising demand for early-stage drug development services, growth in clinical trial material supply services, increasing focus on regulatory compliance and quality standards, expansion of biologics and advanced therapy development, adoption of custom manufacturing solutions for small and large molecules.

The rising number of clinical trials is expected to drive growth in the investigational new drug contract development and manufacturing organization (CDMO) market in the coming years. Clinical trials are carefully designed studies involving human participants to evaluate the safety and efficacy of medical treatments, procedures, or interventions under controlled conditions. The growth in clinical trials is largely driven by the increasing demand for innovative therapies, as rising rates of chronic and complex diseases push pharmaceutical and biotech companies to develop and test new treatments. Investigational new drug CDMOs support clinical trials by streamlining the development and manufacturing of trial-ready drug formulations, ensuring a timely and compliant supply of investigational products for each study phase. For example, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical industry trade association, reported that the total number of industry-sponsored clinical trials initiated in the United Kingdom increased from 411 in 2022 to 426 in 2023, while Phase III trial initiations rose 16.5% over the same period, from 182 to 212. This indicates that the rising number of clinical trials is fueling growth in the investigational new drug CDMO market.

Key companies in the investigational new drug CDMO market are focusing on strategic partnerships to strengthen development capabilities and accelerate clinical entry. Strategic partnerships are formal alliances between two or more organizations that collaborate to achieve shared goals, leveraging each other’s resources, expertise, or strengths while remaining independent entities. For instance, in August 2023, Sartorius AG, a Germany-based life sciences company, partnered with Repligen Corporation, a U.S.-based life sciences company, to launch an integrated system combining the BIOSTAT STR and XCell ATF technologies for upstream process intensification. This collaboration aims to streamline biopharmaceutical production by enhancing efficiency and scalability, demonstrating Sartorius’ continued innovation in bioprocessing solutions and its commitment to advancing the biomanufacturing industry.

In January 2024, Alcami Corporation, a U.S.-based pharmaceutical CDMO, acquired Pacific Pharmaceutical Services for an undisclosed sum. Through this acquisition, Alcami aims to expand its West Coast presence and strengthen its analytical testing and quality control capabilities. Pacific Pharmaceutical Services is a U.S.-based company that provides pharmaceutical testing and quality assurance services.

Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.

North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the investigational new drug CDMO market by increasing the cost of imported raw materials, specialized equipment, and reagents essential for drug development. Segments like injectable formulations and biologics manufacturing are particularly affected, with Asia-Pacific regions such as China and India facing higher import duties. This has increased production costs and led to adjustments in supply chains. On the positive side, tariffs have encouraged investment in domestic manufacturing, local sourcing strategies, and innovation in process efficiencies, enhancing market resilience.

The investigational new drug contract development and manufacturing organization (cdmo) market research report is one of a series of new reports that provides investigational new drug contract development and manufacturing organization (cdmo) market statistics, including investigational new drug contract development and manufacturing organization (cdmo) industry global market size, regional shares, competitors with a investigational new drug contract development and manufacturing organization (cdmo) market share, detailed investigational new drug contract development and manufacturing organization (cdmo) market segments, market trends and opportunities, and any further data you may need to thrive in the investigational new drug contract development and manufacturing organization (cdmo) industry. This investigational new drug contract development and manufacturing organization (cdmo) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An investigational new drug contract development and manufacturing organization (CDMO) is a contract development and manufacturing entity that supports the development and production of pharmaceutical compounds intended for use in clinical trials under an Investigational New Drug application. These organizations operate within the required regulatory frameworks for early-stage drug development, ensuring adherence to guidelines necessary for advancing experimental therapies toward market approval.

The primary products of investigational new drug CDMOs include small molecules and large molecules. Small molecules are low molecular weight compounds that can easily penetrate cell membranes and interact with intracellular targets to influence biological processes. They are utilized in various formulations, such as solid, liquid, and injectable forms, and come with a range of services, including preclinical support, clinical trial material supply, regulatory assistance, and manufacturing services. These offerings are used by multiple end users, including pharmaceutical companies, biotechnology firms, academic institutions, and research organizations.

The investigational new drug contract development and manufacturing organization (CDMO) market includes revenues earned by entities through analytical method development, clinical trial material manufacturing, process development, and quality control testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.